MedGenome Presents its Cancer Vaccine Approach for Lynch Syndrome Patients

MedGenome presented a poster on its study of potential cancer vaccines for Lynch Syndrome patients

Attendees at the 2018 Molecular Medicine Tri-Conference heard MedGenome, a global leader in genomics research and a partner to pharma/biotech companies and academic research institutions conducting complex disease biomarker-identification projects, describe its study of potential cancer vaccines for patients with Lynch syndrome. Lynch syndrome is an inherited condition linked to higher risk of various forms of cancer, including a 70 percent to 80 percent lifetime risk of developing colorectal cancer, with a mean onset age of 45 years.

Dr. Papia Chakraborty, senior scientist and head of immuno-oncology at MedGenome, spoke on “A Personalized Cancer Vaccine Approach to Treat Lynch Syndrome.”